| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition. |
Ongoing |
Diatab |
BE |
18-2017 |
Saudi Ajal |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition. |
Ongoing |
solifenacin succinate |
BE |
Feb-17 |
Saudi Ajal |
| Grazoprevir/Elbasvir For Treatment Of Hepatitis C Virus Genotype 4 Post Kidney Transplant |
Ongoing |
Zepatier |
4 |
2171009 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation |
Ongoing |
Ruxolitinib (INC424) (Jakavi) |
3 |
CINC424D2301 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| <p style="text-align: justify;">Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of<br />Transfusional Iron Overload in Patients with Sickle Cell Disease<br />or Other Anemias</p> |
Ongoing |
Deferiprone |
3b |
LA38-EXT |
Aseer Central Hospital |
| Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients. |
Ongoing |
Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL |
2 |
IRB#17-329 version2 |
King Abdullah Medical City (Makkah) |
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation |
Ongoing |
Ruxolitinib (INC424) (Jakavi) |
3 |
CINC424C2301 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial |
Ongoing |
VITAMIN D3 (CHOLECALCIFEROL) |
3 |
IRB#16-252, V2 |
King Abdullah Medical City (Makkah) |
| A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma |
Ongoing |
Rituximab/ SAIT101 |
3 |
AGB 002 |
Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A Phase 4, Double-Blind, Randomised, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa |
Ongoing |
Adalimumab |
4 |
M15-574 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
